Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,896 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00245466 | Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients | terminated | Phase 2 | 88 | Ferring PharmaceuticalsINDUSTRY | 0 | May 20, 2011 | clinicaltrials |
| NCT01076751 | Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients(PORTREAT) | terminated | — | 82 | SanofiINDUSTRY | 5 | Feb 14, 2011 |
| clinicaltrials |
| NCT00050687 | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | terminated | Phase 1 / Phase 2 | — | Titan PharmaceuticalsINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT00577356 | Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer | terminated | Phase 2 | 6 | Benaroya Research InstituteOTHER | 1 | Jan 20, 2011 | clinicaltrials |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Dec 9, 2010 | clinicaltrials |
| NCT00705822 | Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer(PROSTATA) | terminated | Phase 3 | 54 | SanofiINDUSTRY | 1 | Nov 30, 2010 | clinicaltrials |
| NCT00952666 | Transrectal Ultrasound Imaging of the Prostate Gland and Neurovascular Bundles During Robot-Assisted Laparoscopic Radical Prostatectomy | terminated | Early Phase 1 | 6 | Johns Hopkins UniversityOTHER | 1 | Sep 13, 2010 | clinicaltrials |
| NCT00630799 | Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients | terminated | Phase 3 | 20 | GP-PharmINDUSTRY | 1 | Sep 9, 2010 | clinicaltrials |
| NCT00355758 | UCI 03-72 Prostate Cancer Detection by Serum Proteomic Profiling | terminated | — | 200 | University of California, IrvineOTHER | 1 | Sep 1, 2010 | clinicaltrials |
| NCT00312442 | Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy | terminated | Phase 2 / Phase 3 | 16 | STEBA FranceINDUSTRY | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00258765 | Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy. | terminated | Phase 2 | 1 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2010 | clinicaltrials |
| NCT00176527 | Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 40 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Dec 11, 2009 | clinicaltrials |
| NCT00391950 | Maintaining Bone Strength in Men With Prostate Cancer | terminated | Phase 3 | 300 | NovartisINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT00494338 | Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer | terminated | Phase 2 | 6 | SanofiINDUSTRY | 1 | Oct 1, 2009 | clinicaltrials |
| NCT00089856 | GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer | terminated | Phase 3 | 626 | Cell GenesysINDUSTRY | 8 | Nov 5, 2008 | clinicaltrials |
| NCT00133224 | Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients | terminated | Phase 3 | 408 | Cell GenesysINDUSTRY | 10 | Sep 23, 2008 | clinicaltrials |
| NCT00104130 | Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer | terminated | Phase 2 | 53 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 17, 2008 | clinicaltrials |
| NCT00273338 | DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) | terminated | Phase 3 | 1,200 | NovaceaINDUSTRY | 9 | Nov 6, 2007 | clinicaltrials |
| NCT00132756 | Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 30 | Morton Plant Mease Health CareOTHER | 1 | Nov 8, 2006 | clinicaltrials |
| NCT00040170 | Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer | terminated | Phase 2 | 50 | TransgeneINDUSTRY | 1 | Nov 2, 2006 | clinicaltrials |
| NCT00103428 | Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 69 | Cell GenesysINDUSTRY | 1 | Feb 2, 2006 | clinicaltrials |
| NCT00179738 | A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer. | terminated | Phase 2 | 40 | Celgene CorporationINDUSTRY | 1 | Nov 23, 2005 | clinicaltrials |
Data updated 23 days agoSource updated May 20, 2011source: clinicaltrials